TN-CKE-RESTAURANTS
10.5.2021 15:02:12 CEST | Business Wire | Press release
CKE Restaurants Holdings, Inc., the parent company of Carl’s Jr. and Hardee’s , announced the opening of its 1,000th international restaurant in Madrid, Spain, as they continue to bring bold, craveable burgers and flavors to all corners of the globe. The opening marks a key milestone for the brand as it continues to expand its international footprint across Europe, the Americas, Asia, the Middle East, Australia and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005062/en/
The opening of the new Carl’s Jr. restaurant in Madrid marks the 23rd restaurant in Spain. CKE is continuing to expand across the European market, all the while, delivering new, innovative customer experiences and a menu filled with its impossible-to-ignore flavors.
“The opening of the 1000th international location is a proud moment placing CKE in the top tier of global restaurant chains,” said CEO of CKE Restaurants Ned Lyerly. “Our momentum is building as we have plans to double our international presence in the next five years. We will accelerate growth by focusing on partnerships with exceptional franchise operators who share our vision of offering the most innovative, best tasting food in our industry!”
CKE continues to expand its presence across six continents and has maintained positive same store sales globally for nearly a decade. Earlier this year, the company hit other pivotal international milestones, including opening its 300th restaurant in Mexico; celebrating 40 years of business in the Middle East; expanding across Australia with a flagship restaurant opening in Sydney and later this summer the company will open a restaurant in Charles de Gaulle Airport centered around speed and convenience with a “Grab & Go” station, self-order kiosks and more.
“The 1,000th international restaurant is a major milestone for our company, and we’re thrilled to be able to continue providing guests around the world an iconic taste of California,” said Mike Woida, President of CKE International . “This new Carl’s Jr. location in Spain exemplifies CKE’s commitment to adapt to the consumer landscape and offer new experiences while maintaining craveable flavors.”
With culinary innovation at the forefront, CKE Restaurants will continue to introduce mouth-watering flavors that highlight their brands’ Chargrilled Angus Beef Burgers, crispy Hand-Breaded Chicken Tenders™, their iconic range of products that everyone knows and loves, and additionally CKE will create local adaptations that are region-specific, such as the Morita Burger in Mexico, Poutine in Canada, and more.
Follow Carl’s Jr. and Hardee’s on social media for the latest product news and promotional offers.
Twitter:
@CarlsJr
and @Hardees
Instagram:
@CarlsJr
and @Hardees
Facebook:
www.facebook.com/carlsjr
and www.facebook.com/hardees
About CKE Restaurants Holdings, Inc.
CKE Restaurants Holdings, Inc. (“CKE”), a privately held company based in Franklin, Tennessee, runs and operates Carl’s Jr. and Hardee’s, two beloved regional brands, known for one-of-a-kind premium and innovative menu items such as 100 percent Black Angus Thickburgers®, Made from Scratch™ Biscuits and Hand-Breaded Chicken Tenders™. With both a US and international footprint, Carl’s Jr. Restaurants LLC and Hardee’s Restaurants LLC have over 3,900 franchised or company-operated restaurants in 44 states and 40 foreign countries and U.S. territories. For more information about CKE, please visit www.ckr.com or its brand sites at www.carlsjr.com and www.hardees.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom